Rebel News reporter Avi Yemini spoke to AstraZeneca Chief Executive Officer Marc Dunoyer as he entered the World Economic Forum meeting in Davos, Switzerland.
Dunoyer’s biography on AstraZeneca’s website:
Marc became CEO of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca’s Chief Financial Officer from November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.
Yemini questioned Dunoyer about his thoughts on COVID-19 jab mandates, despite the well-known fact that the experimental shots don’t stop transmission of any pathogen.
Dunoyer said they were a “very good idea.”
“How do you think about the vaccine mandates around the world? If you still think it was a good idea,” Yemini asked Dunoyer.
“It was a very good idea, yes,” Dunoyer replied.
“It obviously didn’t stop the transmission, so what’s the reason for that?” Yemini rebutted.
“Transmission is only one of them. The protection of people is probably the most important objective in the vaccination programs,” Dunoyer said.
Watch the exchange below:
I bumped into the AstraZeneca boss as he entered the WEF today. Marc now admits his vaccine never stopped the spread but justified the mandates anyways.
He scrambled behind the restricted area before I could ask about the recent rise in "sudden deaths".
But I'm here all week. pic.twitter.com/5EMSefjv6I
— Avi Yemini (@OzraeliAvi) January 17, 2023
Rebel News noted:
Not only was AstraZeneca’s vaccine not effective in stopping the spread of COVID-19, but it is also no longer administered in multiple countries around the world because of clotting issues and vaccine injuries, particularly in men under the age of 40.
Everyone under the age of 40 in the UK is being offered an alternative to AstraZeneca's COVID vaccine after concerns over blood clotting.https://t.co/kxZYC94EtA
— Sky News Australia (@SkyNewsAust) May 8, 2021
Earlier this month, ICAN, through its attorneys, retrieved information from the United Kingdom’s FDA equivalent – the Medicines and Healthcare Products Registry Agency (MHRA) — about the biodistribution of the AstraZeneca COVID-19 jab.
From ICAN:
One of these studies investigated biodistribution of the AstraZeneca vaccine, meaning where it goes in the body after injection, in mice. This study revealed that the viral vector DNA did not remain localized in the injection site but instead migrated to other organs. Disturbingly, the study found vector DNA in the sciatic nerves, bone marrow, livers, lungs, and spleens of the mice following vaccination.
The study documents further revealed that, in early 2021, AstraZeneca was forced to amend its data sheet for the vaccine after concluding that there may have been a causal association between the vaccine and serious hypersensitivity including anaphylaxis.
Despite the life-threatening risks of taking the AstraZeneca COVID-19 jab, the company’s executive still defends forcing people to take the shot to keep their jobs.
.
.
.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!